1 / 5

Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift towards Targeted mAbs

While 99% of currently marketed gastric cancer drugs are small molecules, this dominance could give way to more innovative treatments in future, as the pipeline consists of 29% monoclonal antibodies (mAbs) says new research “Gastric Cancer - Early Stage Pipeline Innovation Shows Shift towards Targeted mAbs”<br><br>Download Sample:https://marketreportscenter.com/reports/252384/frontier <br>

SamCollins
Download Presentation

Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift towards Targeted mAbs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift towards Targeted mAbs Publisher : GBI Research Publication Date: Mar 2016 Number of Pages: 70 Single User license: USD 6995 Site User license: USD 13990 Enterprisewide User license: USD 20985 Contact us : info@marketreportscenter.com call: 1-646-883-3044

  2. Scope: • - What is the pathophysiology of gastric cancer? • - How is gastric cancer diagnosed? • - What are the current treatment options? • - What are the common targets and mechanisms of action of pipeline therapies? • - Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients? • - What implications will the increased focus on targeted therapies have on the future of gastric cancer treatment? • - What are the most promising first-in-class targets for gastric cancer? • - Will the current first-in-class targets have a broader therapeutic potential across the industry? • - How do deal frequency and value compare between target families and molecule types? • - How do licensing and co-development deals compare between first-in-class and non-first-in-class profiles? Contact us : info@marketreportscenter.com call: 1-646-883-3044

  3. Analysis of the gastric cancer treatment pipeline, stratified by stage of development, molecule type and molecular target. It includes information on the current clinical and commercial landscape, and the composition of the gastric cancer therapeutics market in terms of dominant molecule types and targets, as well as highlighting current unmet needs. • While 99% of currently marketed gastric cancer drugs are small molecules, this dominance could give way to more innovative treatments in future, as the pipeline consists of 29% monoclonal antibodies (mAbs), according to business intelligence provider GBI Research. • The company’s latest report states that there are currently 241 products in the gastric cancer pipeline, a number of which have different mechanisms of action and targets to the dominant marketed therapies. Contact us : info@marketreportscenter.com call: 1-646-883-3044

  4. Reasons to buy : • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies • Visualize the composition of the gastric cancer market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market. • Analyzethe gastric cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating gastric cancer. • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail. • Identify commercial opportunities in the gastric cancer deals landscape by analyzing trends in licensing and co-development deals and producing a list of gastric cancer therapies that are not yet involved in deals, and may be potential investment opportunities.Gastric Cancer Drug Development Shifting from Small Molecules to Monoclonal Antibodies Contact us : info@marketreportscenter.com call: 1-646-883-3044

  5. Full Report at : https://marketreportscenter.com/reports/252384/frontier-pharma-gastric-cancer-early-stage-pipeline-innovation-shows-shift-towards-targeted-mabs Reach us at: info@marketreportscenter.com sam@marketreportscenter.com Visit us : www.marketreportscenter.com Call us at : 1-646-883-3044 (US) +91- 20-41217796 (IND) Follow us: FacebookTwitterLinkedin

More Related